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Abstract
CRISPR/Cas9 has become a powerful 
method for making changes to the genome of 
many organisms. First discovered in bacteria 
as part of an adaptive immune system, 
CRISPR/Cas9 and modified versions have 
found widespread use in genome engineering 
and in the activation or repression of gen 
expression. As such, CRISPR/Cas9 promises 
to accelerate cancer research by providing an 
efficient technology to dissect mechanisms 
of tumorigenesis, identify targets for drug 
development, and possibly arm cells for cell-
based therapies. Here, we review the current 
applications of the CRISPR/Cas9 technology 
for cancer research and therapy. We highlight 
the impact of CRISPR/Cas9 in generating 
organoid and mouse models of cancer. Finally, 
we provide an overview of the first clinical 
trials applying CRISPR/Cas9 as a therapeutic 
approach against cancer.
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Introduction
Cancer is one of the main causes of 
disease-associated mortality, with a rising 
incidence worldwide. Progress has been 
made in the prevention and treatment 
of many cancers, leading to prolonged 
survival or even cures. The main pillar of 
innovation in cancer therapy has been an 
improved understanding of the underlying 
tumor biology (Yin et al., 2019). 
Recently, genome engineering was 
greatly accelerated by the development 
of CRISPR/Cas9 technologies (Mimoune 
et al., 2021). Since its first use in 2013 as a 
genome editing tool in mammalian cells, 
the CRISPR/Cas9 toolbox has been con-
tinuously expanded, enabling not only 
the modification of the genomic sequence 
of cells and organisms, but also the intro-
duction of epigenetic and transcriptional 
modifications (Zhan et al., 2019). 
In this review, we describe how 
CRISPR/Cas9 has opened new avenues 
for cancer research. In addition to its 
application as an effective screening 
method in functional cancer genomics, 
we outline how CRISPR/Cas9 can be used 
to explore the non-coding genome of 
cancer. Furthermore, we describe novel 
in vitro and in vivo cancer models that can 
be engineered by CRISPR/Cas9. Finally, 
we review the first clinical trials applying 
CRISPR as a therapy against cancer.
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What is CRISPR?
Introduction to gene editing
What is gene editing?
Gene editing involves inserting, 
deleting, modifying and replacing DNA 
in the genome of living organisms. It 
began in the 1970s, when scientists 
bombarded plants with radiation to 
cause random mutations. Gene editing 
started to show great promise with the 
incorporation of engineered gene-editing 
nucleases (Zink finger, Transcription 
Activator-Like Effectors, Meganucleases 
and CRISPR-Cas systems), which 
introduced the concept of targeted 
genome editing. The nucleases induce 
double-stranded breaks (DBS) into 
the targeted genomic locus. Nuclease-
induced DSBs can be repaired by one 
of two different pathways that operate 
in nearly all cell types and organisms: 
nonhomologous end-joining (NHEJ) and 
homology-directed repair (HDR). The 
NHEJ pathway involves the cell’s own 
repair system by joining the DNA ends 
of a DSB, this process is prone to errors 
and can lead to the efficient introduction 
of insertion/deletion mutations (indels) 
of various lengths, which can disrupt 
gene function. The HDR pathway relies 
on a recombination of the DSBs ends and 
a homologous piece of DNA present in 
the nucleus, this system can be used to 
introduce precise and desired mutations 
to the target genome (Figure 1) (Sander 
and Joung, 2014). 
Gene editing before CRISPR
Zinc-Finger Nucleases
Zinc-finger nucleases (ZFN) are 
fusions between the Cys2-His2 zinc-
finger protein and the cleavage domain 
of the Fok I restriction endonuclease that 
have been adopted as gene-targeting 
tools. In essence, they are targetable 
DNA cleavage reagents (Caroll, 2011; Gaj 
et al., 2016). Their discovery came when 
Chandrasekaran realized that the natural 
restriction enzyme, Fok I, has physically 
separable binding and cleavage activities, 
and that the cleavage domain could be 
guided and cutting could be redirected 
by replacing the recognition domains 
with alternative ones (Carroll, 2011). 
Of these alternatives, the Cys2His2 zinc 
fingers (ZFs) were the most useful, where 
usually 3 to 4 zinc fingers are fused to 
the Fok I cleavage domain, where each 
finger is comprised of 30 amino acids 
residues and interacts with three base 
pairs of DNA with occasional overlap 
from an adjacent domain. In order for 
the Fokl domain to cut DNA, it needs 
to dimerize (a chemical reaction that 
joins two molecular subunits, resulting 
in the formation of a single unit known 
as dimer. The dimer interface is weak, 
and to solve this problem and achieve 
better specificity, the best way to 
achieve cleavage is to construct two 
opposed sets of fingers directed to 
neighbouring sequences. When both 
sets are bound to their recognition sites, 
high local concentration facilitates the 
dimerization process and cleavage, 
resulting in a double-strand break (DSB) 
in the DNA (Caroll, 2011; Gaj et al., 2016). 
Despite great promise, the difficulty 
of constructing ZFs has hindered the 
widespread of this approach as it remains 
really challenging to create ZF-domains 
Figure 1. The basic working principle of major 
genome-editing technologies (Adli, 2018)
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that can effectively recognize all DNA 
triplets outside specialized laboratories 
(Gaj et al., 2016). 
TALE Nucleases
Transcription activator-like effectors 
(TALE) are bacterial proteins discovered 
in 2009, when scientists revealed the code 
behind TALE’s capability to recognize 
DNA dps (DNA-binding proteins from 
starved cells), enabling the creation of 
custom TALE nucleases comprised of 
an amino-terminal TALE DNA-binding 
domain fused to a carboxy-terminal 
Fok I cleavage domain, enabling the 
editing of nearly any gene. In many 
ZFNs, the Fokl domain is responsible 
for dimerization and cutting, and unlike 
ZFs, which recognize DNA triplets, each 
TALE repeat recognizes only a single 
bp. Typically, TALEs are assembled to 
recognize from 12 to 20 dps with more 
bases typically leading to higher genome-
editing specificity. TALEs have a highly 
repetitive structure, making their delivery 
to the cell (through lentiviruses or a single 
adeno-associated virus) less efficient, 
though they have been reported to show 
improved specificity and reduced toxicity 
compared to some ZFNs. Engineering 
TALE arrays is much easier, reducing the 
amount of time and experience needed to 
assemble a functional nuclease (Boch et 
al., 2009; Gaj et al., 2016).
Meganucleases
The final members of the targeted 
nuclease family, also known as homing 
endonucleases, are highly specific 
DNA cleaving enzymes that have been 
engineered to be used for applications 
that require targeted gene modification 
(Stoddard, 2014). Discovered in the 1970s, 
these enzymes recognize and cleave long 
DNA sequences after making extensive 
sequence-specific contacts with their 
DNA substrate, showing superlative 
specificity. Their biggest limitation 
however is that the recognition and 
cleavage domains are not separable, and 
thus their repurposing and engineering 
is challenging, and their utility is limited 
(Stoddard, 2014; Gaj et al., 2016).
CRISPR
What is CRISPR?
CRISPR is a distinct array of 
29-nucleotide repeat sequences separated 
by various 32-nt spacer sequences, 
discovered in 1987 when they were 
observed in certain bacteria. Since then, 
they have been found to be in 40% of 
all sequenced bacterial genomes and in 
nearly 90% of archaea. Although scientists 
have hypothesized about the function 
of the CRISPR sequences for years, the 
nature of their function has only recently 
been elucidated; in 2005, it was observed 
that the spacer sequences actually 
originate from phage genomes, and that 
these bacteria and archaea were immune 
to viruses with genomes identical to the 
sequences carried in the CRISPR arrays 
(Mojica et al., 2005; Bolotin et al., 2005; 
Makarova et al., 2011; Song et al., 2016). 
Independently, several types of Cas 
genes were found adjacent to CRISPR 
sequences. When analysed in detail, 
the adjacent sequences were found to 
contain domains characteristic of several 
nucleases, a helicase, a polymerase 
and various RNA-binding proteins. 
These proteins were initially thought to 
constitute a novel DNA repair system 
in prokaryotic cells; however, with the 
observation that these Cas genes always 
neighboured the CRISPR array, and 
the spacer sequences were identical to 
fragments of the viral genome, a new 
hypothesis emerged: that the CRISPR-
Cas system serves as a critical immune 
system to protect bacteria and archaea 
from pathogen invasions (Makarova et al., 
2011; Song et al., 2016). This hypothesis 
was confirmed in 2007 when it was shown 
that that integration of a short phage-
specific sequence into the CRISPR array 
of Streptococcus thermophilus conferred 
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resistance to the cognate phage, and 
a complete loss of immunity towards 
the virus with the existence of a single 
mismatch between the CRISPR spacer 
and the target virus sequence (Barrangou 
et al., 2007).
Classification and Associated proteins
Given the fact that CRISPR is a 
fairly new technology, several of its 
properties and functions have only 
recently been understood or are yet to 
be elucidated. This is also the case for 
its associated proteins Cas, and as such, 
new classifications are released every few 
years. The current classification includes 
2 classes, 6 types and 33 subtypes. 
Class one uses a complex of multiple 
Cas proteins to degrade foreign nucleic 
acids, includes Types I, III and IV, and 
is comprised of 16 subtypes. Class two 
uses a single large Cas protein to induce 
DNA degradation, includes Types II, V 
and VI, and 17 subtypes. The subtypes 
are characterized by a “signature gene” 
found almost exclusively in that category 
(Makarova et al., 2020).
How does the CRISPR/Cas system work?
The process in which the CRISPR-
Cas systems mediate immunity against 
foreign genetic elements is divided into 
three stages — Adaptation, expression 
and interference — that fall under two 
subsystems. The first subsystem is 
highly conserved and is known as the 
“information processing” subsystem, and 
includes the adaptation stage, and the 
proteins involved in it (Cas1 and Cas2) 
are conserved between most prokaryotic 
beings. The second subsystem, called 
the “executive” subsystem, includes the 
expression and interference stages, and 
unlike the in first subsystem, the proteins 
in this subsystem vary greatly between 
different organisms (Makarova et al., 
2011).
The adaptation stage revolves 
around the integration of short pieces 
of virus DNA sequences or plasmid 
into the CRISPR loci. This insertion 
process is known as “spacer acquisition” 
and it is triggered by viral invasions, 
where a single virus-derived resistance-
conferring spacer, with a characteristic 
length of approximately 30 bp at the 
leader side of a CRISPR locus. This is 
accompanied by the duplication of a 
repeat sequence, thus creating a new 
spacer–repeat unit (Barrangou et al., 
2007; Makarova et al., 2011; McGinn and 
Marraffini, 2018).
The adaptation stage starts with the 
recognition of foreign nucleic acids or 
“protospacers”. This step is of great 
importance for prokaryotic cells to avoid 
the integration of self-targeting spacers 
from the host’s own chromosome into 
CRISPR, which leads to autoimmunity 
and even cell death. To avoid self-
targeting, the CRISPR system employs 
various mechanisms that are biased to 
acquire only foreign genetic elements. 
CRISPR/Cas exploits the nature of 
the viral genome to stimulates spacer 
acquisition from double-strand breaks, 
carried out by relying on DNA repair 
machinery of the host, which binds 
only to the free ends of double stranded 
DNA to perform end resection during 
homologous recombination. This creates 
a biased recognition for viral DNA, as 
the bacterial chromosome is circular and 
lacks free DNA ends. Furthermore, the 
actions of the DNA repair system are 
inhibited by the presence of chi sites, 
which are eight nucleotide sequence 
motifs. The concentration of these Chi 
sites is much higher in host genome than 
in invader DNA, which constrains spacer 
acquisition from the host genome and 
differentiates self from non-self-nucleic 
acids. It remains unresolved if and how 
the DNA captured by the repair system 
can be used for spacer integration, with 
the leading hypothesis that Cas1 and 
Cas2 physically associates with the DNA 
repair component to directly uptake 
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degradation products (Levy et al., 2015; 
McGinn and Marraffini, 2018). 
Another important aspect of the 
recognition step is that the CRISPR-
Cas system must select protospacers 
that can be functional spacers under 
type specific targeting requirements. 
This is to ensure the cleavage of foreign 
DNA and to prevent the cleavage of the 
spacer sequence in the CRISPR array 
during the interference stage. Different 
types have different requirements, i.e. in 
types I and II, the acquisition machinery 
preferentially samples genes flanked by 
a “protospacer-adjacent motif”, though 
the two types achieve this differently: in 
type I, the Cas1–Cas2 complex has direct, 
sequence-specific interactions with the 
Protospacer Adjacent Motif (PAM) that 
biases acquisition to PAM-adjacent 
protospacers, while in type II, this 
selectivity for PAM-adjacent protospacers 
is the PAM-interacting domain of Cas9 
that interacts directly with the Cas1–Cas2 
complex (McGinn and Marraffini, 2018). 
In type III systems, the discrimination 
between self and non-self is achieved via 
the 5′ tag of the mature crRNA, which 
must not base pair with the target to 
enable degradation by the complex (Hille 
and Charpentier, 2016). 
The expression stage involves the 
transcription process of the CRISPR 
locus to generate RNA-protein guides. 
All systems transcribe the CRISPR 
locus and generate the long primary 
transcript pre-crRNA which, depending 
on whether the CRISPR has repeats or 
not, may contain a series of secondary 
structures (hairpins). From here, the pre-
crRNA is processed down and catalysed 
by endoribonucleases into short crRNAs, 
and the endoribonuclease either operate 
as a large complex like “Cascade” 
(CRISPR associated complex for antiviral 
defence) in the case of type I CRISPR-Cas 
system in Escherichia coli, or as a single 
enzyme, such as Cas6 in type III CRISPR-
Cas system of the archaeon Pyrococcus 
furiosus.
In Type I systems, the complex remains 
associated with the Mature crRNA, while 
in Type III systems, Cas 6 passes the 
crRNA to a complex (a Type III complex) 
Figure 2. The two classes of CRISPR/Cas systems and their modular organization (Makarova et al., 
2020)
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to undergo ruler-based sequence-
unspecific processing and trimming at 
the 3’ end, yielding a mature crRNA 
with a defined 5′ end and variable 3′ end 
(Makarova et al., 2011; Rath et al., 2015). 
On the other end of the spectrum, there 
are Type II systems, which employ a very 
different approach for crRNA biogenesis. 
The maturation process is carried out by 
the host RNase III in the presence of a 
trans-encoded RNA (tracrRNA) that base 
pairs with the pre-crRNA. This process 
is stabilised by the Cas9 protein and 
yields an intermediate form of crRNA, 
which is further processed by unknown 
mechanisms to reach the mature crRNA 
(Rath et al., 2015; Hille and Charpentier, 
2016). 
The interface stage starts with mature 
crRNAs, where in Type I CRISPR systems 
use Cascade-like complexes to bind the 
foreign DNA, then stimulate the Cas3 
protein to carry out degradation, while 
Type II relies on a single protein (Cas9) 
to induce immunity. The Cas9 protein, 
guided by the Trans-crRNA duplex, 
scans the cell and when it encounters 
the matching nucleic acid it performs 
a double strand break at a very specific 
site. Type III CRISPR systems are able to 
target both DNA and RNA, by relying 
on Cas10-Csm (types III-A and III-D) 
and Cas10-Cmr (types III-B and III-C) 
complexes, where the Cas10 cleaves the 
DNA while Csm3 and Cmr4 cleave the 
transcribed mRNA in type III-A and type 
III-B CRISPR-Cas systems, respectively 
(Figure 2) (Hille and Charpentier, 2016).
How it is used in gene editing?
Different CRISPR systems in gene editing
The one common theme among all 
CRISPR systems is their ability to induce 
target specific DNA changes, whether 
through degradation or double stranded 
breaks. This qualify almost all of these 
systems for use in genome editing, 
though some systems are too complex 
for practical use. Nowadays, the Type II 
CRISPR-Cas9 system is the most widely 
used due to the simple “NGG” PAM 
sequence requirements (Figure 3) (Adli, 
2018). 
Figure 3. Major application areas of CRISPR/Cas-based technologies beyond genome editing (Adli, 
2018)
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The CRISPR/Cas9 system in gene 
editing
The brilliance of the Type II CRISPR/
Cas9 system lies in in the mixture of 
versatility and simplicity it provides. 
This type relies on the Cas9 endonuclease 
of Streptococcus pyogenes (spCas9) to 
cleave the target DNA. The Cas9 protein 
is comprised of two cleaving domains, 
the HNH domain and the RuvC-like 
nuclease domain. The union of crRNA 
and tracrRNA “gRNA” guides the Cas9 
to the target site to perform sequence-
specific cleavage by simple interaction 
of crRNA by base pairing. The target 
sites must lie immediately 5′ of a PAM 
sequence that matches the canonical form 
5′-NGG. This flexibility allows scientists 
to easily direct the Cas9 nuclease cleaving 
activity to any DNA sequence that is 
comprised of 18-24nt followed by NGG, 
simply by altering the first 18-24 nt of the 
gRNA (Sander and Joung, 2014; Rodrigez-
Rodrigez et al., 2019). Since 2012, when it 
was shown that the CRISPR/Cas9 system 
could be programable with chemical 
RNAs that retain the properties of the 
gRNA, the system has been implemented 
successfully for gene editing, and for the 
control of different types of biological 
systems, ranging from bacteria to in 
vitro human cancer cells and human 
pluripotent stem cells to whole organisms 
like the zebrafish, all while reducing 
the cost and time necessary for such 
alterations. Targeting of a new genomic 
locus for gene deletion, mutation and 
targeted insertion can be done rapidly 
through the generation of a gRNA, making 
CRISPR a powerful tool for research and 
drug development. However, being an 
acquired evolutionary arm that gives 
immunity mostly against viruses that 
frequently undergo mutations, a slightly 
less specific CRISPR system would be 
more advantageous to the host, and as 
such the CRISPR/Cas9 system allows 
cleavage at genomic locations that are 
partially complementary to the gRNA. 
This hinders the accuracy of the system 
and remains one of the most important 
outstanding issues can result in undesired 
consequences (Sander and Joung, 2014; 
Adli, 2018; Rodrigez-Rodrigez et al., 
2019). 
Several approaches have been taken 
to increase the specificity of the CRISPR/
Cas9 system through the re-engineering 
of the existing spCas9. The first proof of 
concept came in a study that showed that 
a specific point mutation significantly 
increased the specificity of SpCas9. 
Another approach is the replacement 
of the traditional SpCas9 with a mutant 
variant (nSpCas9) which cuts a single 
strand through the inactivation of a 
nuclease domain RuvC or HNH. In this 
case, and much like the ZFN and TALEN 
methods, two nCas9 are needed to 
target opposite strands of DNA in close 
proximity, with each nCas9 guided by 
its own sgRNA reducing the off-target 
activity by 50 to 1,500 times. Furthermore, 
the fusion of dCas9 (catalytically inactive 
Cas9) with the DNA cleavage domain of 
Fok I, much like the previous approach 
with the presence of two distinct sgRNAs, 
substantially reduces off-target activity 
(Kleinstiver et al., 2016; Adli, 2018; 
Rodrigez-Rodrigez et al., 2019). Apart 
from re-engineering of the Cas9 protein, 
efforts also focused on modifying the 
sgRNA. Interestingly, it was proved that 
both increasing and decreasing the length 
of the sgRNA guiding sequence by a few 
base pairs enhanced targeting specificity 
(Cho et al., 2014; Fu et al., 2014).
CRISPR/Cas9 beyond gene editing
Due to its ease of use and flexibility, 
CRISPR/Cas9 provides a versatile tool 
for applications that are revolutionizing 
many genetic studies beyond gene 
editing. Soon after the discovery of dCas9 
and the ability to acquire catalytically 
inactive Cas9 that strongly binds to 
the DNA target sequence, interfering 
with the activity of other DNA binding 
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proteins without initiating any cleavage 
processs, scientists have tried to exploit 
this property to regulate gene expression, 
mediated epigenome editing and 
screening (Figure 4).
Another use of dCas9 is in live cell 
chromatin imaging. The organization of 
chromatin structure in the 3D nuclear 
space plays a critical role in regulating lin-
eage-specific gene expression, as such the 
dCas9 is used in fusion with fluorescent 
proteins or labels to target specific and 
repetitive regions enabling their imaging. 
Non-repetitive region imaging is more 
challenging due to interference of back-
ground fluorescence signals (free-floating 
fluorescently labelled dCas9 proteins). 
Typically, this requires transfection of as 
many as 26–36 unique sgRNAs to achieve 
live cell imaging of a non-repeat genom-
ic region (Adli, 2018). Chromatin imag-
ing allows for a better understanding of 
their 3D structure, but beyond imaging, 
one of the most exciting applications for 
the CRISPR/Cas9 system is chromatin 
topology. This involves engineering arti-
ficial chromatin loops between regulato-
ry genomic regions, providing a means 
to manipulate endogenous chromatin 
structures to understand their function 
and contribution to gene expression. An 
elegant way to achieve this is through 
the fusion of two dimerisable protein 
domains ABI1 and PYL1 (taken from the 
plant-based abscisic acid signalling path-
way) with two dCas9. This forces chro-
matin loop formation between the distal 
enhancer and promoter regions, allowing 
for targeted chromatin topology (Figure 
5) (Morgan et al., 2017; Adli, 2018).
Figure 4. CRISPR for genetic screening (Yin et al., 2019)
Figure 5. CRISPR use in chromatin topology 
(Pickar-Oliver and Gersbach, 2019)
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CRISPR and Oncology
Given its extreme versatility and 
ease of use, the CRISPR/Cas9 system 
represents an extraordinary therapeutic 
potential for treating different diseases 
originating from known genetic 
dysfunctions, and facilitating our 
understanding of the ambiguous aspects 
of complex genetic diseases through the 
creation of cell or animal models. Current 
preclinical research on genome editing 
primarily concentrates on viral infections, 
cardiovascular diseases (CVDs), 
metabolic disorders, primary defects of 
the immune system, haemophilia and 
muscular dystrophy. However, genetic 
diseases and their therapeutic trials cannot 
be discussed without addressing cancer 
(Yin et al., 2019; Li et al., 2020). Ever since 
it was discovered that cancer originate 
from DNA changes, scientists have been 
attempting to find ways to comprehend 
and correct these mutations. Although 
several technological advancements 
have been made regarding gene editing 
and regulation over the years, none have 
been satisfactory enough, up until the 
conception of CRISPR in 2013. The system 
has taken cancer research by storm, 
revolutionizing several fields of oncology 
from Cancer modelling and screening to 
immunotherapy and treatment (National 
Cancer Institute, 2020).
CRISPR for cancer modelling
To treat cancer, we first have to 
conceptualize it, by identifying the 
genes and their mutations that initiate 
carcinogenesis and drive tumour 
progression in genetically tractable 
models. This is of a great importance for 
the development of clinically effective 
therapeutics. Whole-genome sequencing 
of cancer cells reveals the multiple point 
drive mutations and as such, cellular 
and animal models, can be established 
using these data in order to understand 
the molecular mechanisms underlying 
tumorigenic responses. This was a 
lengthy and costly process that required 
laborious gene targeting, hindering 
the advancement of cancer research. 
However, his limitation is now alleviated 
by the CRISPR/Cas9 system, which in 
recent years have been extensively used 
to produce cancer models (Ratan et al., 
2018; Yin et al., 2019).
Cellular Modelling
Because it relies on the gRNA rather 
than protein–DNA interactions, the 
CRISPR/Cas9 system allows for fast yet 
inexpensive modelling of mammalian 
cells with single genetic alteration. 
This has substantially accelerated 
pharmacological studies of targeted 
therapies, especially regarding the 
validation of gene function and their 
involvement in tumorigenesis (Yin et 
al., 2019). An important example is the 
MELK controversy. Maternal embryonic 
leucine zipper kinase (MELK) is an 
enzyme encoded by the MELK gene, and 
it was believed that the MELK enzyme 
is essential for cancer proliferation. 
However, through the CRISPR-mediated 
silencing of the MELK gene, it was found 
to have no effect on cancer cells growth 
and as such is fully dispensable (Huang et 
al., 2017; Lin et al., 2017; Yin et al., 2019). 
Another example involves the gene with 
the most mutations in human cancer: the 
p53 tumor suppressor gene. CRISPR/
Cas9 was used to validate the p53-
reactivating molecules nutlin and RITA, 
which were both initially identified as 
compounds that exhibit antiproliferative 
activity in tumour cells with an active 
p53, but not in p53-mutated or p53-
deleted cells, nutlin was confirmed to 
inhibit tumour proliferation via a p53-
dependent mechanism, but the activity of 
RITA was found to be p53-independent 
(Wanzel et al., 2016; Yin et al., 2019). 
Beyond the validation of certain genes 
identified in cancer research, the CRISPR/
Cas9 system could be used to disrupt 
functional genes or induce mutations 
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to identify drug resistance properties in 
cultured cells. Furthermore, scientists use 
the CRISPR/Cas9 system to manipulate 
multiple genes in a cell to explore the 
genetic complexity of malignancies (Yin 
et al., 2019). But it doesn’t stop there: the 
system’s versatility allows for the study 
of tumour biology and its interaction 
with the micro-environment through 
genome edited organoids, which are 
tiny, self-organized three-dimensional 
tissue cultures derived from stem cells. 
Through the use of the CRISPR/Cas9 
system, these organoids can be modelled 
to replicate much of the complexity of an 
organ, or to express selected aspects of it 
by producing only certain types of cells 
(Yin et al., 2019; Stemcell Technologies, 
2020).
In vivo modelling
To fully understand how cancer 
operates, it is indispensable to study the 
interactions in whole organisms. The 
establishment of the CRISPR/Cas9 system 
in organism modelling has facilitated the 
study of cancers in living organisms, as 
the ability to edit the genome of somatic 
cells to induce driver mutations is more 
practical and cost efficient by margins than 
the manipulation of germline cells used 
before CRISPR. Moreover, the genetic 
manipulation of somatic cells resembles 
the naturally occurring driver mutations. 
The CRISPR/Cas9 system is introduced 
to the somatic cells through viral or 
plasmid delivery systems. The viruses 
used in the viral delivery system are: 
lentivirus or retrovirus. Lentiviral 
vectors enable stable expression of Cas9 
and sgRNA and can therefore enable 
efficient gene editing in vivo. Lentiviral 
vectors have been widely used to deliver 
CRISPR locally in the target organs 
of interest to create animal models of 
brain, breast, colon, lung or pancreatic 
cancer. Despite their utility, lentiviruses 
have certain limitations, such as the fact 
that their delivery is surgery-dependent 
in some tissues like the brain, and the 
need to account for the random genomic 
integration of lentivirus to exclude 
lentivirus-induced off-target effects.
Adeno-associated virus and adeno-
virus: due to their broad- ranging tissue 
tropisms, AAS and adenoviruses have 
seen a great range of use in genome ed-
iting to generate animal models of can-
cer. These viruses can be delivered to 
the lungs quite easily with simple intra-
nasal or intratracheal injection. Howev-
er, the downside of their cargo capac-
ity is that they are smaller than other 
viruses used for delivery, hindering 
their delivery range. Another limitation 
is their ability to generate a strong im-
mune response in the liver, which might 
compromise the disease phenotype. 
Hydrodynamic injection or electropora-
tion of plasmids: a high volume and pres-
sure injection of the tail vein is a well-es-
tablished method of delivering plasmids 
to the liver in rodents. This approach does 
not require any viruses for delivery, and 
and it has been shown to reliably mod-
el point mutations of tumour suppressor 
genes and oncogenes in the liver. Howev-
er, this approach presents the lowest effi-
ciency rate and the risk of liver damage 
(Yin et al., 2019).
CRISPR and Immunotherapy
For decades, surgery, chemotherapy, 
and radiotherapy have been the 
treatments of choice for cancer. However, 
in the last decade, the focus has been 
changing slowly but surely towards 
immunotherapy. CRISPR stands at the 
forefront of the technological advances 
that are facilitating the shift from general 
therapies to precise, targeted and 
immune induced therapies (Liu and Guo, 
2018; Schirmacher, 2018; Yin et al., 2019; 
Esfahani et al., 2020; Waldman et al., 2020). 
CRISPR systems are being incorporated 
and adapted to improve the efficacy of 
immunotherapies by enhancing potency, 
reducing toxicity and manufacturing 
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cost, and facilitating the discovery of new 
immunotherapeutic strategies (Yin et al., 
2019). The CRISPR/Cas9 system has been 
used to establish the most promising 
approaches in cancer immunotherapy. 
For instance, in the Immune checkpoint 
blockade approach, scientists have 
relied on CRSIPR screening to identify 
checkpoint mediator genes and their 
functional expression. Such screening 
was used to point out the mechanisms 
by which the tumour cells avoid immune 
cells, enabling more effective engineering 
of the native T-Cell Receptor (TCRs) or 
Chimeric Antigen Receptors (CARs) (Yin 
et al., 2019; Khalaf et al., 2020).
Direct Tumour targeting with the 
CRISPR/Cas9 system
This approach could be described as 
going back to the basics of CRISPR/Cas9 
gene editing capabilities. Cancer cells 
present specific genes which are usually 
the product of driver mutations that are 
absent in normal cells. This sparked the 
idea of using the CRISPR/Cas9 system to 
induce DSBs by relying on a pair of Cas9 
nickases targeting two neighbouring 
cancer-specific genes. After that a suicidal 
gene (encoding a prodrug converting 
enzyme) with homology to the sequences 
surrounding the breakpoints is delivered 
via an adenoviral vector to enable its 
introduction into the genome via HDR 
(Chen et al., 2017; Yin et al., 2019).
Conclusions
Since its development as a genome 
editing tool, the CRISPR/Cas9 
technology has revolutionized biology 
by providing a simple and versatile 
method to manipulate the genome and 
epigenome across a broad range of 
organisms. The potential of CRISPR/
Cas9 for both basic and translational 
cancer research is just beginning to 
unfold. In the future, pooled CRISPR 
screens will provide a comprehensive 
set of essential genes across most cancer 
cell lines. This resource, combined with 
the available information on the genetic 
and epigenetic characteristics of cancer 
cell lines, will enable the extensive 
identification of synthetic lethal 
interactions and facilitate the discovery 
of novel drug targets. The future use of 
CRISPR/Cas9 in translational medicine 
will largely depend on the ability to 
develop Cas9 variants with minimal or 
no off-target effect, and novel methods to 
improve the yet inefficient engineering 
of precise genetic changes by homology 
directed repair. Furthermore, future 
improvements of viral and non-viral 
delivery methods will be necessary 
to improve the in vivo application of 
CRISPR/Cas9, laying the ground for 
the therapeutic use of CRISPR in the 
future. In summary, the development 
of CRISPR/Cas9 technology has and 
will greatly accelerate cancer research in 
many areas.
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CRISPR/Cas9 postala je snažna metoda 
za unošenje promjena u genom brojnih 
organizama. Prvi put otkriven u bakterijama 
kao dio prilagodljivog imunološkog sustava, 
CRISPR/Cas9 i njegove modificirane verzije 
u širokoj su uporabi u inženjeringu genoma 
i aktivaciji ili suzbijanju ekspresije gena. 
Kao takav, CRISPR/Cas9 obećava ubrzanje 
istraživanja raka, osiguravajući učinkovitu 
tehnologiju za analizu mehanizama 
tumorogeneze, identifikaciju ciljeva za razvoj 
lijekova i moguće „naoružanje“ stanica za 
terapije na bazi stanica. U ovom je radu dat 
pregled današnjih primjena CRISPR/Cas9 
tehnologije u istraživanju i liječenju raka, a 
naglašen je utjecaj CRISPR/Cas9 u generiranju 
organoidnih modela raka i modela raka 
miša. Na kraju, dat je pregled prvih kliničkih 
ispitivanja koja primjenjuju CRISPR/Cas9 kao 
terapijski pristup protiv raka.
Ključne riječi: CRISPR/Cas9, rak, 
ispitivanje, primjena
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